edurant 25 mg comprimate filmate
janssen-cilag international nv - rilpivirinum - comprimate filmate - 25 mg
jcovden (previously covid-19 vaccine janssen)
janssen-cilag international nv - adenovirus type 26 encoding the sars-cov-2 spike glycoprotein (ad26.cov2-s) - covid-19 virus infection - vaccinuri - jcovden is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 years of age and older. utilizarea acestui vaccin ar trebui să fie în conformitate cu recomandările oficiale.
covid-19 vaccine janssen 8.92 log10 iu/dose suspensie injectabilă
janssen-cilag international nv - vacc. covid-19 (ad26.cov2-s[recombinant]) - suspensie injectabilă - 8.92 log10 iu/dose
arexvy
glaxosmithkline biologicals s.a. - respiratory syncytial virus recombinant glycoprotein f stabilised in the pre-fusion conformation (rsvpref3) produced in chinese hamster ovary (cho) cells by recombinant dna technology - infecții ale virusului sincițial respirator - vaccinuri - arexvy is indicated for active immunisation for the prevention of lower respiratory tract disease (lrtd) caused by respiratory syncytial virus in adults 60 years of age and older. utilizarea acestui vaccin ar trebui să fie în conformitate cu recomandările oficiale.
sayanaject 104 mg
pfizer manufacturing belgium nv - belgia - medroxyprogesteronum - susp. inj. - 104mg - contraceptive hormonale pentru uz sistemic progestative
sayana 104 mg
pfizer manufacturing belgium nv - belgia - medroxyprogesteronum - susp. inj. in seringa preumpluta - 104mg - contraceptive hormonale pentru uz sistemic progestative
sayanaject 104 mg
pfizer manufacturing belgium nv - belgia - medroxyprogesteronum - susp. inj. - 104mg - contraceptive hormonale pentru uz sistemic progestative
abrysvo
pfizer europe ma eeig - respiratory syncytial virus, subgroup a, stabilized prefusion f protein / respiratory syncytial virus, subgroup b, stabilized prefusion f protein - infecții ale virusului sincițial respirator - vaccinuri - abrysvo is indicated for:passive protection against lower respiratory tract disease caused by respiratory syncytial virus (rsv) in infants from birth through 6 months of age following maternal immunisation during pregnancy. vezi secțiunile 4. 2 și 5. active immunisation of individuals 60 years of age and older for the prevention of lower respiratory tract disease caused by rsv. utilizarea acestui vaccin ar trebui să fie în conformitate cu recomandările oficiale.
nuvaring sistem cu cedare vaginala 11,7 mg + 2,7 mg
schering-plough central east ag - etonogestrelum + ethinylestradiolum - sistem cu cedare vaginala - 11,7 mg + 2,7 mg
comirnaty 10 mcg/doză concentrat pentru dispersie injectabilă
biontech manufacturing gmbh - combinaţie - concentrat pentru dispersie injectabilă - 10 mcg/doză